PMID- 1593608
OWN - NLM
STAT- MEDLINE
DCOM- 19920702
LR  - 20131121
IS  - 0380-0903 (Print)
IS  - 0380-0903 (Linking)
VI  - 33
DP  - 1992 Apr
TI  - Intravenous immunoglobulin therapy: magic or black magic.
PG  - 94-7
AB  - Intravenous immunoglobulin (IVIG) therapy has been used not only as replacement 
      treatment for immunodeficiency, but also as treatment of autoimmune diseases, 
      specifically Kawasaki disease, systemic juvenile arthritis and juvenile 
      dermatomyositis. In Kawasaki disease, IVIG reduces the incidence of coronary 
      artery abnormalities, as well as rapidly improving clinical and laboratory 
      variables such as fever and rash, platelet count, white blood cell count and 
      serum albumin. Furthermore, a single high dose of 2 g/kg is as effective as 400 
      mg/kg x 4 days. In systemic juvenile arthritis, followup of at least one year 
      demonstrated that monthly treatment with IVIG resulted in improvement of systemic 
      disease in 10/11 patients, allowed for cessation of prednisone treatment in 7/8 
      patients and significant improvement of arthritis in 8 patients. In juvenile 
      dermatomyositis, we report 2 uncontrolled trials of IVIG treatment that resulted 
      in significant clinical improvement and steroid-sparing. In contrast, IVIG 
      treatment of systemic lupus erythematosus (SLE) resulted in improvement in 3 
      patients, but exacerbation or new onset of renal disease in 3 patients. Overall, 
      our report demonstrates that IVIG has been effective both in a controlled trial 
      in Kawasaki disease and in uncontrolled trials in systemic juvenile arthritis and 
      juvenile dermatomyositis. We suggest that IVIG should be used cautiously in SLE.
FAU - Barron, K S
AU  - Barron KS
AD  - Department of Pediatrics, Baylor College of Medicine, Houston, TX.
FAU - Sher, M R
AU  - Sher MR
FAU - Silverman, E D
AU  - Silverman ED
LA  - eng
PT  - Journal Article
PT  - Review
PL  - Canada
TA  - J Rheumatol Suppl
JT  - The Journal of rheumatology. Supplement
JID - 7806058
SB  - IM
CIN - J Rheumatol. 1993 Dec;20(12):2176-7. PMID: 8014961
MH  - Arthritis, Juvenile/therapy
MH  - Dermatomyositis/therapy
MH  - Humans
MH  - *Immunization, Passive
MH  - Injections, Intravenous
MH  - Lupus Erythematosus, Systemic/therapy
MH  - Mucocutaneous Lymph Node Syndrome/therapy
MH  - Rheumatic Diseases/*therapy
RF  - 19
EDAT- 1992/04/01 00:00
MHDA- 1992/04/01 00:01
CRDT- 1992/04/01 00:00
PHST- 1992/04/01 00:00 [pubmed]
PHST- 1992/04/01 00:01 [medline]
PHST- 1992/04/01 00:00 [entrez]
PST - ppublish
SO  - J Rheumatol Suppl. 1992 Apr;33:94-7.